Shares of Arecor Therapeutics plc (LON:AREC – Get Free Report) fell 0.3% during trading on Thursday . The stock traded as low as GBX 85.26 and last traded at GBX 85.26. Approximately 1,182 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 24,282 shares. The stock had previously closed at GBX 85.50.
Arecor Therapeutics Trading Down 3.5%
The firm has a market capitalization of £31.34 million, a price-to-earnings ratio of 41.50 and a beta of -0.18. The company has a current ratio of 4.35, a quick ratio of 6.24 and a debt-to-equity ratio of 1.52. The company has a fifty day moving average price of GBX 68.05 and a two-hundred day moving average price of GBX 67.21.
Arecor Therapeutics Company Profile
Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.
Featured Articles
- Five stocks we like better than Arecor Therapeutics
- Priced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits
- These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
- Not Just Banks: 3 Trading Stocks to Watch After the Fed Rate Hike
- MarketBeat Week in Review – 09/14 – 09/18
Receive News & Ratings for Arecor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arecor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
